Skip Navigation

European Heart Journal 2002 23(18):1471-1479; doi:10.1053/euhj.2001.3154
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ricci, R.
Right arrow Articles by Santini, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ricci, R.
Right arrow Articles by Santini, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Efficacy of a dual chamber defibrillator with atrial antitachycardia functions in treating spontaneous atrial tachyarrhythmias in patients with life-threatening ventricular tachyarrhythmias

R. Riccia,f1, C. Pignalberia, M. Disertorib, A. Capuccic, L. Padelettid, G. Bottoe, S. Toscanoa, F. Miragliaf, A. Grammaticof and M. Santinia

a San Filippo Neri Hospital, Rome, Italy
b Santa Chiara Hospital, Trento, Italy
c Civile Hospital, Piacenza, Italy
d Careggi Hospital, Florence, Italy
e S. Anna Hospital, Como, Italy
f Medtronic, Italy

revised December 17, 2001; accepted December 18, 2001

Abstract

Background Atrial fibrillation has a high incidence in patients wearing an implantable cardioverter defibrillator for ventricular tachyarrhythmias and may lead to palpitations, heart failure, angina, stroke and inappropriate defibrillator discharge. The aim of the study was to evaluate the efficacy of a dual chamber defibrillator with atrial antitachycardia functions in treating spontaneous atrial tachyarrhythmias.

Methods One hundred and twelve patients, 88 male, mean age 64±11 years, were enrolled. Seventy-six had ischaemic heart disease, 21 idiopathic dilated cardiomyopathy, nine other heart diseases, six no structural heart disease. The mean left ventricular ejection fraction was 40±11%. Sixty-two had prior atrial tachyarrhythmias.

Results Follow-up lasted 11±9 months (range 1–42). Among 933 ventricular tachyarrhythmia episodes, 100% of ventricular fibrillation and 92% of ventricular tachycardia were successfully cardioverted. Among 414 detected sustained atrial tachyarrhythmias, 195 were classified as atrial tachycardia (47·1%), 192 as atrial fibrillation (46·4%) and 27 (6·5%) as sinus rhythm. The detection-positive predictive value was 93·5%. Therapy success rates: antitachy pacing on atrial tachycardia=71·3% (crude estimate); 66·1% (adjusted estimate); 50 Hertz on atrial fibrillation=36·2% (crude estimate); 13·5% (adjusted estimate); atrial shock on atrial fibrillation=62·5% (mean energy 7·8±14·1J). Shock efficacy was 32% when delivered energy was ≤2 atrial defibrillation threshold at implant and 92% when >2. Duration of successfully treated atrial episodes was significantly lower than that of unsuccessfully treated (6±26min vs 42±60).

Conclusions Atrial antitachy pacing and shock therapies demonstrated very high efficacy in treating atrial tachyarrhythmias in defibrillator patients. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.

Key Words: Atrial fibrillation, ventricular tachyarrhythmias, dual chamber defibrillator, atrial antitachycardia therapies, cardioversion

f1 Correspondence: Dr Renato Ricci, M.D., Via Antonio Sogliano 84, 00164 Rome, Italy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
EuropaceHome page
R. P. Ricci, A. Quesada, J. Almendral, F. Arribas, C. Wolpert, P. Adragao, M. Zoni-Berisso, X. Navarro, T. DeSanto, A. Grammatico, et al.
Dual-chamber implantable cardioverter defibrillators reduce clinical adverse events related to atrial fibrillation when compared with single-chamber defibrillators: a subanalysis of the DATAS trial
Europace, May 1, 2009; 11(5): 587 - 593.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
S. P. Bhavnani, C. I. Coleman, C. M. White, C. A. Clyne, R. Yarlagadda, D. Guertin, and J. Kluger
Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy
Europace, July 1, 2008; 10(7): 854 - 859.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
J. Almendral, F. Arribas, C. Wolpert, R. Ricci, P. Adragao, E. Cobo, X. Navarro, A. Quesada, and the DATAS Steering Committee and Writing Committee
Dual-chamber defibrillators reduce clinically significant adverse events compared with single-chamber devices: results from the DATAS (Dual chamber and Atrial Tachyarrhythmias Adverse events Study) trial
Europace, May 1, 2008; 10(5): 528 - 535.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
L. Mont, R. Ruiz-Granell, J. G. Martinez, J. R. Carmona, M. Fidalgo, E. Cobo, M. Riera, X. Navarro, and on behalf of the Prevention or Termination (POT) S
Impact of anti-tachycardia pacing on atrial fibrillation burden when added on top of preventive pacing algorithms: results of the prevention or termination (POT) trial
Europace, January 1, 2008; 10(1): 28 - 34.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
R. Gradaus, K. Seidl, T. Korte, E. Himmrich, H. Wieneke, A. Schuchert, W. Bauer, J. Gerss, C. G. Wollmann, M. Borggrefe, et al.
Reduction of ventricular tachyarrhythmia by treatment of atrial fibrillation in ICD patients with dual-chamber implantable cardioverter/defibrillators capable of atrial therapy delivery: the REVERT-AF Study
Europace, July 1, 2007; 9(7): 534 - 539.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
M. Gulizia, S. Mangiameli, S. Orazi, G. Chiaranda, G. Boriani, G. Piccione, N. DiGiovanni, A. Colletti, C. Puntrello, G. Butera, et al.
Randomized comparison between Ramp and Burst+ atrial antitachycardia pacing therapies in patients suffering from sinus node disease and atrial fibrillation and implanted with a DDDRP device
Europace, July 1, 2006; 8(7): 465 - 473.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
F. Drago, M. S. Silvetti, G. Grutter, and A. De Santis
Long term management of atrial arrhythmias in young patients with sick sinus syndrome undergoing early operation to correct congenital heart disease
Europace, July 1, 2006; 8(7): 488 - 494.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
A. Quesada, J.ús Almendral, F. Arribas, R. Ricci, C. Wolpert, P. Adragao, E. Cobo, X. Navarro, and on behalf DATAS investigators
The DATAS rationale and design: a controlled, randomized trial to assess the clinical benefit of dual chamber (DDED) defibrillator
Europace, January 1, 2004; 6(2): 142 - 150.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
M. Santini and R. Ricci
Atrial fibrillation and heart failure
Europace, January 1, 2003; 5(s1): S55 - S59.
[Full Text] [PDF]


Home page
Eur Heart JHome page
M.J.P. Raatikainen and H.V. Huikuri
Management of atrial fibrillation in patients with implantable cardioverter defibrillator. Do all need a dual chamber device?
Eur. Heart J., September 2, 2002; 23(18): 1412 - 1414.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.